To our knowledge, these are the first randomized trial data providing insights into the treatment of iron deficiency with intravenous iron in patients with HFrEF taking an SGLT2 inhibitor, although any conclusions are limited by the small number of patients taking an SGLT2 inhibitor at baseline. The gene discussed is SLC5A2; the disease is Iron deficiency anemia.